Additionally, the exploratory analysis of the IMmotion150 trial reported that a T-effector immune gene signature displayed an association with the expression of PD-L1 and the tumor infiltration of T CD8 + cells, resulting in an increased response to atezolizumab, with a higher ORR and a prolonged PFS (36). Here, CD8A is linked to neoplasm.